why choose us

300×250 Ad Slot

Research Article: Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies

Date Published: 2023-12-03

Abstract:
The risk of developing cutaneous T cell lymphoma (CTCL) in patients using psoriasis biologics has not been well characterized. The goals of this review were to investigate the incidence of CTCL in patients with psoriasis receiving biologic therapy in clinical trials and psoriasis registries, and to review cases of CTCL and biologic use reported in scientific publications.

Introduction:
Psoriasis is a common, multisystem inflammatory disease characterized by erythematous, scaling patches, and plaques. Psoriasis affects roughly 125 million people worldwide (3% prevalence) and is associated with comorbidities such as psoriatic arthritis, cardiovascular disease, diabetes mellitus, and obesity [1, 2]. The underlying pathogenesis involves dysregulated cutaneous immunity with dysfunction of T1 and T17 cells, dendritic cells, keratinocytes, fibroblasts, and macrophages. This results in keratinocyte…

Read more

300×250 Ad Slot